Medical Strategy is one of the leading independent healthcare investment advisers in Europe. In line with its core competence, the company focuses exclusively on managing and advising equity portfolios in the healthcare sector.

Company profile: download here. 

In 2018, Medical Strategy was awarded with the Finance Research AWARD. In the segment of Independent Asset Managers in Germany, the company was rated as “Outstanding“.

At the “Funds Europe Awards” in London in November 2018, Medical Strategy received a special commendation in the category “European Specialist Investment Firm of the Year”

2018:

 

20172017
20162015
Urkunde_III_GM_2015_DrMichaelFischer_de

 

 

 

 

News

28.02.19: Roadshow BÖRSE EXPRESS Wien
Februar 2019: Interview mit Mario Linimeier
Januar 2019: BOERSE-ONLINE.DE
14.01.19: apoAsset beteiligt sich mit 25,1 % an Medical Strategy

Fonds

Medical BioHealth EUR, ISIN LU0119891520 – share classes for private investors (No Minimum Initial Purchase)
Medical BioHealth EUR H, ISIN LU0228344361 – share classes for private investors, currency-hedged (No Minimum Initial Purchase)
Medical BioHealth I, ISIN LU0294851513 – share classes for institutional investors (Minimum Initial Purchase 100,000 Euros)
Medical BioHealth I H, ISIN LU0295354772 – share classes for institutional investors, currency-hedged (Minimum Initial Purchase 100,000 Euros)